Skip to main content Skip to search Skip to main navigation
News: Europe

EC: Harmonised Standards for Medical Device Sterilisation

The European Commission adopted two implementing decisions on the sterilisation of medical devices. These decisions were made in accordance with the regulations governing medical devices and in vitro diagnostics (IVDs) in the EU.

Harmonised standards play a crucial role in ensuring compliance with regulatory requirements. To this end, the Commission collaborated with the European Committee for Standardization (CEN) and the European Committee for Electrotechnical Standardization (Cenelec) to revise existing standards and to develop new standards pertaining to the sterilization of various medical devices and diagnostics.

The Commission has incorporated the proposed standards into two implementing decisions. The first decision ((EU) 2024/817) adds three sterilization-related standards to an existing annex within the IVDs regulatory framework ((EU) 2021/1195). The second decision ((EU) 2024/815) extends this by incorporating sterilisation standards into an existing decision on medical devices ((EU) 2021/1182), together with additional guidance on, inter alia, medical gloves, packaging for terminally sterilised medical devices and health care products.


Sources:

Commission Implementing Decision (EU) 2024/817 of 6 March 2024

Commission Implementing Decision (EU) 2024/815 of 6 March 2024

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next